Medication Scheme Implementation Guide
1.0.0 - trial-use
Medication Scheme Implementation Guide
1.0.0 - trial-use
Medication Scheme Implementation Guide, published by TEHIK. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/TEHIK-EE/ig-ee-medication-scheme/ and changes regularly. See the Directory of published versions
| Official URL: https://fhir.ee/OperationDefinition/Interactions | Version: 1.0.0 | |||
| Standards status: Trial-use | Maturity Level: 1 | Computable Name: Interactions | ||
The interactions operation is used to get interactions for given Medications or MedicationPlan.
URL: POST [base]/Medication/$interactions
This is NOT an idempotent operation.
Klient-süsteemide töövoo paremaks toetamiseks on võimalik kasutada operation't analoogselt tänasele retseptikeskuse x-tee teenusele rets.koostoime_list:
URL: [base]/Medication/$interactions
URL: [base]/Patient/$interactions
| Use | Name | Scope | Cardinality | Type | Binding | Documentation |
| IN | subject | 1..1 | Patient | Patient | ||
| IN | input | 0..* | Medication | List of new medications. If not empty then only interactions between input medications will be returned. Old medication interactions won't be returned if they don't interact with new medications. | ||
| OUT | return | 1..1 | Bundle | Found interactions |
Näide on tehtud olukorrale, kus lisatavat ravimit kaasa ei anta, on ainult patsiendi viide:
Näidispäring patsiendi viitega
{
"resourceType": "Parameters",
"parameter": [
{
"name": "subject",
"valueReference": {
"reference": "Patient/123"
}
}
]
}
Näidis-väljund olukorras, kus on leitud üks koostoime, mis mõjutab kahte ravimiskeemi rida:
Näidisvastus ühe koostoimega
{
"resourceType": "Bundle",
"type": "collection",
"entry": [
{
"resourceType": "ClinicalUseDefinition",
"id": "medication-interaction1",
"meta": {
"profile": [
"https://fhir.ee/StructureDefinition/ee-tis-medication-interaction"
]
},
"contained": [
{
"resourceType": "Medication",
"id": "medication-interaction1-varfariin",
"meta": {
"profile": [
"https://fhir.ee/StructureDefinition/ee-tis-medication-epc"
]
},
"doseForm": {
"coding": [
{
"system": "https://fhir.ee/CodeSystem/ravimvormid",
"code": "738",
"display": "tablett"
}
]
},
"ingredient": [
{
"item": {
"concept": {
"coding": [
{
"system": "https://fhir.ee/CodeSystem/toimeained",
"code": "11360",
"display": "varfariin"
}
]
}
},
"isActive": true,
}
]
},
{
"resourceType": "Medication",
"id": "medication-interaction1-ibuprofeen",
"meta": {
"profile": [
"https://fhir.ee/StructureDefinition/ee-tis-medication-epc"
]
},
"ingredient": [
{
"item": {
"concept": {
"coding": [
{
"system": "https://fhir.ee/CodeSystem/toimeained",
"code": "9210",
"display": "ibuprofeen"
}
]
}
},
"isActive": true
}
]
}
],
"type": "interaction",
"category": [
{
"text": "D. Kliiniliselt oluline koostoime, mida tuleb pigem vältida"
},
{
"text": "4.Andmed on saadud asjakohase patsiendirühma seas korraldatud kontrollitud uuringutest"
}
],
"affected": [
{
"reference": "MedicationStatement/123"
},
{
"reference": "MedicationStatement/456"
}
],
"subject": [
{
"reference": "#medication-interaction1-varfariin"
}
],
"status": {
"coding": [
{
"code": "active"
}
]
},
"interaction": {
"interactant": [
{
"itemReference": {
"reference": "#medication-interaction1-ibuprofeen"
}
}
],
"type": {
"coding": [
{
"system": "http://hl7.org/fhir/interaction-type",
"code": "drug-drug",
"display": "drug to drug interaction"
}
],
"text": "drug to drug interaction"
},
"effect": {
"concept": {
"text": "MSPVA ja varfariini kooskasutamine võib põhjustada tugevat veritsust. Seedetrakti ülaosa verejooksu oht on 2–3 korda suurem võrreldes varfariini monoteraapiaga."
}
},
"incidence": {
"text": "D4"
},
"management": [
{
"text": "Varfariinravi patsientidel tuleb üldiselt vältida MSPVA kasutamist. Veritsusriski hindamiseks ei piisa ainult INRi väärtuse jälgimisest, kuna MSPVA mõjutab ka trombotsüütide funktsiooni. Kui samaaegset kasutamist ei saa vältida, kaaluda mao kaitseks prootonpumba inhibiitorite (nt lansoprasool, omeprasool või pantoprasool) kasutamist. Kui suukaudset antikoagulanti ja MSPVA-d kasutatakse ühel ajal, tuleb patsienti verejooksu sümptomite suhtes jälgida."
}
]
}
}
]
}
Näidis sisend olukorrast, kus kaasa on antud nii patsiendi viide kui ka lisatav ravim:
**Näidispäring patsiendi viite ja lisatava ravimiga**
{
"resourceType": "Parameters",
"parameter": [
{
"name": "subject",
"valueReference": {
"reference": "Patient/123"
}
},
{
"name": "input",
"resource": {
"resourceType": "Medication",
"id": "medication-interaction1-varfariin",
"meta": {
"profile": [
"https://fhir.ee/StructureDefinition/ee-tis-medication-epc"
]
},
"doseForm": {
"coding": [
{
"system": "https://fhir.ee/CodeSystem/ravimvormid",
"code": "738",
"display": "tablett"
}
]
},
"ingredient": [
{
"item": {
"concept": {
"coding": [
{
"system": "https://fhir.ee/CodeSystem/toimeained",
"code": "11360",
"display": "varfariin"
}
]
}
},
"isActive": true
}
]
}
}
]
}